C4 Therapeutics, Inc. (CCCC)
Chart Events
Performance Outlook
| Previous Close | 7.07 |
| Open | 7.04 |
| Bid | 7.23 x 800 |
| Ask | 7.24 x 2900 |
| Day's Range | 6.71 - 7.34 |
| 52 Week Range | 4.84 - 51.21 |
| Volume | |
| Avg. Volume | 1,152,119 |
| Market Cap | 357.683M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.64 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CCCC
Related Research
- C4 Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 04/13/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 months agoArgus Research
- GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT8634, an orally bioavailable BiDAC™ degrader targeting BRD9 for the treatment of SMARCB1-perturbed cancers, includin
- Zacks
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C – – Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors – – Potential of TORPEDO® Platform Demonstrated at AACR with Pre-clinical Presentations on CFT7455, CFT8634 and CFT1946 – – Cash, Cash Equivalents and Marketable Securities Total $421.7 million as of
